EUVIMEDEUVIMED entdecken
Crossref

Genotype III-Based Japanese Encephalitis Vaccines Exhibit Diminished Neutralizing Response to Reemerging Genotype V

Ah-Ra Lee, Woo-Jin Kim, Haeyoun Choi, Sang-Hyun Kim, Su-Yeon Hong, Sang-Mu Shim, Hee Il Lee, Jae Min Song, Seong-Jun Kim iD, Tomohiro Ishikawa iD, Ji-Man Kang iD, Hyeon-Seok Eom und 1 weitere

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiae589 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Ah-Ra Lee und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Graduate School of The Catholic University of Korea, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Japanese Encephalitis Vaccines, Encephalitis Virus, Japanese, Antibodies, Neutralizing, Encephalitis, Japanese. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Ministry of Health and Welfare, Republic of Korea, National Institute of Health, Republic of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Japanese encephalitis (JE) has been predominantly controlled through vaccination. However, the isolation of JE virus (JEV) genotype V (GV) in China in 2009, and the subsequent alarming increase in JE cases in the Republic of Korea since 2010, present a new challenge.

Methods

Serum samples from individuals vaccinated with genotype III (GIII)-based JE vaccines were analyzed for neutralizing seroresponse to GV isolates.

Results

Serum from immunocompromised pediatric patients vaccinated with an inactivated JE vaccine showed higher 50% plaque reduction neutralization test geometric mean titer (GMT) against GIII Nakayama (11 358; 95% confidence interval [CI], 1790–29 658), but lower GMTs against GV isolates: GV Muar (499; 95% CI, 0–2437), GV 43279 (308; 95% CI, 159–582), and GV 43413 (231; 95% CI, 108–738). Similarly, 32 healthy volunteers receiving a live attenuated JE vaccine achieved 100% seroprotection against GIII Nakayama with GMT of 338 (95% CI, 304–651) at 1 month postvaccination. However, GMTs against GV isolates were 123 (95% CI, 102–446) for GV Muar, 81 (95% CI, 63–168) for GV 43279, and 107 (95% CI, 100–322) for GV 43413, not achieving 100% seroprotection against these isolates. At 6 months postvaccination, GMT against Nakayama increased to 696 (95% CI, 409–2353), while remaining similar for GV isolates.

Conclusions

Our study underscores that current GIII-based vaccines do not provide comparable protection against GV JEVs, impacting individuals in both current and potential endemic regions, as well as travelers to these regions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Japanese Encephalitis VaccinesEncephalitis Virus, JapaneseAntibodies, NeutralizingEncephalitis, JapaneseAntibodies, ViralHumansGenotypeChildFemaleMaleChild, PreschoolNeutralization TestsAdultAdolescentRepublic of KoreaYoung AdultVaccines, AttenuatedInfantVaccines, Inactivated

Stichwörter der Autor:innen

Japanese encephalitis viruscross-reactivitygenotype Vneutralizing antibodyvaccine

Substanzen

Japanese Encephalitis VaccinesAntibodies, NeutralizingAntibodies, ViralVaccines, AttenuatedVaccines, Inactivated

Autor:innen und Institutionen

  • Department of Medical Sciences, Graduate School of The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Division of Acute Virus Diseases, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.
  • Division of Vectors and Parasitic Diseases, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.
  • School of Biopharmaceutical and Medical Sciences, Sungshin Women's University, Seoul, Republic of Korea.
  • Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.

ORCID-Profile: Seong-Jun Kim, Tomohiro Ishikawa, Ji-Man Kang, Sang-Uk Seo

Förderung

  • Ministry of Health and Welfare, Republic of Korea
  • National Institute of Health, Republic of Korea

Zitieren

APA

Lee, A. R., Kim, W. J., Choi, H., Kim, S. H., Hong, S. Y., Shim, S. M., Lee, H. I., Song, J. M., Kim, S. J., Ishikawa, T., Kang, J. M., Eom, H. S., & Seo, S. U. (2025). Genotype III-Based Japanese Encephalitis Vaccines Exhibit Diminished Neutralizing Response to Reemerging Genotype V. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae589

Vancouver

Lee AR, Kim WJ, Choi H, Kim SH, Hong SY, Shim SM, et al. Genotype III-Based Japanese Encephalitis Vaccines Exhibit Diminished Neutralizing Response to Reemerging Genotype V. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae589

BibTeX
@article{Lee2025,
  author = {Lee, Ah-Ra and Kim, Woo-Jin and Choi, Haeyoun and Kim, Sang-Hyun and Hong, Su-Yeon and Shim, Sang-Mu and Lee, Hee Il and Song, Jae Min and Kim, Seong-Jun and Ishikawa, Tomohiro and Kang, Ji-Man and Eom, Hyeon-Seok and Seo, Sang-Uk},
  title = {Genotype III-Based Japanese Encephalitis Vaccines Exhibit Diminished Neutralizing Response to Reemerging Genotype V},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiae589}
}
Kostenlos starten →